A coalition of 51 attorneys general in the US filed an antitrust complaint in federal court alleging that key individual executives and manufacturers of dermatological claim generic drugs engaged in a widespread conspiracy to artificially inflate and manipulate prices, reduce competition for generic drugs sold across the country, reported Bloomberg.
The antitrust complaint filed by AGs including New York’s Letitia James named as defendants 26 generic, dermatological drug manufacturers and 10 individual executives at these companies.
The complaint alleges broad, coordinated, and systematic antitrust violations, price-fixing, market allocating, and the rigging of bids for more than 80 different topical, generic drugs.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Microsoft Demands FTC Investigation into Alleged Antitrust Probe Leak
Dec 3, 2024 by
CPI
American Express Must Face Class Action Lawsuit, US Judge Rules
Dec 3, 2024 by
CPI
Ted Cruz Seeks Probe into European Influence on US AI Laws
Dec 3, 2024 by
CPI
Microsoft Faces £1.2 Billion Lawsuit in UK Over Cloud Software Licensing Practices
Dec 3, 2024 by
CPI
Bimbo Seeks $2B in Damages from Maple Leaf Foods in Canada Bread Price-Fixing Case
Dec 3, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead